264 related articles for article (PubMed ID: 21425596)
1. [Antimicrobial susceptibility of clinical isolates of aerobic Gram-positive cocci and anaerobic bacteria in 2006].
Yamaguchi T; Yoshida I; Itoh Y; Tachibana M; Takahashi C; Kaku M; Kanemitsu K; Okada M; Horikawa Y; Shiotani J; Kino H; Ono Y; Baba H; Matsuo S; Asari S; Toyokawa M; Matsuoka K; Kusano N; Nose M; Murase M; Miyamoto H; Saikawa T; Hiramatsu K; Kohno S; Yanagihara K; Yamane N; Nakasone I; Maki H; Yamano Y
Jpn J Antibiot; 2010 Dec; 63(6):431-56. PubMed ID: 21425596
[TBL] [Abstract][Full Text] [Related]
2. [Antimicrobial susceptibility of clinical isolates of aerobic gram-positive cocci and anaerobic bacteria in 2008].
Yoshida I; Yamaguchi T; Kudo R; Fuji R; Takahashi C; Oota R; Kaku M; Kunishima H; Okada M; Horikawa Y; Shiotani J; Kino H; Ono Y; Fujita S; Matsuo S; Kono H; Asari S; Toyokawa M; Kusano N; Nose M; Horii T; Tanimoto A; Miyamoto H; Saikawa T; Hiramatsu K; Kohno S; Yanagihara K; Yamane N; Nakasone I; Maki H; Yamano Y
Jpn J Antibiot; 2012 Feb; 65(1):49-72. PubMed ID: 22808693
[TBL] [Abstract][Full Text] [Related]
3. [Comparative antimicrobial activity of RP 59,500 (quinupristin-dalfopristin), the first semisynthetic injectable streptgramin, against gram-positive cocci and other recent clinical pathogens].
Nakashio S; Iwasawa H; Iino S; Shimada J
Jpn J Antibiot; 1997 Oct; 50(10):844-53. PubMed ID: 9412874
[TBL] [Abstract][Full Text] [Related]
4. [Surveillance on gram-positive bacteria isolated from patients with hospital acquired infections or community acquired infections].
Li JT; Li Y; Wang J;
Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):365-74. PubMed ID: 12820911
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial susceptibility of quinupristin/dalfopristin tested against gram-positive cocci from Latin America: results from the global SMART (GSMART) surveillance study.
Sader HS; Jones RN; Ballow CH; Biedenbach DJ; Cered RF;
Braz J Infect Dis; 2001 Feb; 5(1):21-31. PubMed ID: 11290311
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species.
Marchese A; Salerno A; Pesce A; Debbia EA; Schito GC
Chemotherapy; 2000; 46(4):253-66. PubMed ID: 10859431
[TBL] [Abstract][Full Text] [Related]
7. [In vitro activity of daptomycin and other antimicrobial agents against 499 strains of gram-positive cocci causing bloodstream infection].
Yang QW; Wang H; Sun HL; Xu YC; Xie XL; Chen MJ
Zhonghua Nei Ke Za Zhi; 2009 Mar; 48(3):220-4. PubMed ID: 19576091
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial activity of everninomicin against clinical isolates of Enterococcus spp., Staphylococcus spp., and Streptococcus spp. tested by Etest.
Terakubo S; Takemura H; Yamamoto H; Ikejima H; Kunishima H; Kanemitsu K; Kaku M; Shimada J
J Infect Chemother; 2001 Dec; 7(4):263-6. PubMed ID: 11810596
[TBL] [Abstract][Full Text] [Related]
9. [An antimicrobial resistance surveillance of gram-positive cocci isolated from 12 teaching hospitals in China in 2009].
Sun HL; Wang H; Chen MJ; Liu YM; Hu ZD; Liao K; Chu YZ; Lei JE; Zhang B; Yu YS; Hu BJ; Sun ZY; Zhang Z; He QY
Zhonghua Nei Ke Za Zhi; 2010 Sep; 49(9):735-40. PubMed ID: 21092441
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo activities of novel 2-(thiazol-2-ylthio)-1beta-methylcarbapenems with potent activities against multiresistant gram-positive bacteria.
Ueda Y; Sunagawa M
Antimicrob Agents Chemother; 2003 Aug; 47(8):2471-80. PubMed ID: 12878507
[TBL] [Abstract][Full Text] [Related]
12. In vitro activities of RWJ-54428 (MC-02,479) against multiresistant gram-positive bacteria.
Chamberland S; Blais J; Hoang M; Dinh C; Cotter D; Bond E; Gannon C; Park C; Malouin F; Dudley MN
Antimicrob Agents Chemother; 2001 May; 45(5):1422-30. PubMed ID: 11302805
[TBL] [Abstract][Full Text] [Related]
13. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--I. Gram-positive bacteria].
Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T
Jpn J Antibiot; 2002 Feb; 55(1):1-21. PubMed ID: 11977919
[TBL] [Abstract][Full Text] [Related]
14. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--I. Gram-positive bacteria].
Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T
Jpn J Antibiot; 2003 Oct; 56(5):437-57. PubMed ID: 14692380
[TBL] [Abstract][Full Text] [Related]
15. Comparative in-vitro activities of quinupristin-dalfopristin against Gram-positive bloodstream isolates.
Schouten MA; Hoogkamp-Korstanje JA
J Antimicrob Chemother; 1997 Aug; 40(2):213-9. PubMed ID: 9301986
[TBL] [Abstract][Full Text] [Related]
16. [Bacteria isolated from surgical infections and their susceptibilities to antimicrobial agents: special references to bacteria isolated between July 1996 and June 1997].
Mashita K; Shinagawa N; Ishikawa S; Hirata K; Denno R; Mukaiya M; Mizuno A; Ishibiki K; Ushijima Y; Kinoshita H; Morimoto K; Aikawa N; Yamazaki M; Fujimoto M; Iwai S; Kato K; Tanimura H; Ohnishi H; Maeda T; Sato T; Tanaka N; Inoue F; Iwagaki H; Yura J; Tanaka S
Jpn J Antibiot; 1999 May; 52(5):398-430. PubMed ID: 10480049
[TBL] [Abstract][Full Text] [Related]
17. Activity of linezolid against Gram-positive cocci isolated in French hospitals as determined by three in-vitro susceptibility testing methods.
Muller-Serieys C; Drugeon HB; Etienne J; Lascols C; Leclercq R; Nguyen J; Soussy CJ
Clin Microbiol Infect; 2004 Mar; 10(3):242-6. PubMed ID: 15008946
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of telavancin and comparators against selected groups of Gram-positive cocci.
Hope R; Chaudhry A; Adkin R; Livermore DM
Int J Antimicrob Agents; 2013 Mar; 41(3):213-7. PubMed ID: 23298432
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of teicoplanin against gram-positive cocci.
Allouch P; Pina P; Chaplain C; Delarbre JM; Geffroy F; Grasmick CP; Marcolin M; Morel A; Pangon B; Rio Y; Sédaillan A
Pathol Biol (Paris); 2000 Oct; 48(8):792-5. PubMed ID: 11244609
[TBL] [Abstract][Full Text] [Related]
20. Comparative in vitro activities of SMT19969, a new antimicrobial agent, against Clostridium difficile and 350 gram-positive and gram-negative aerobic and anaerobic intestinal flora isolates.
Goldstein EJ; Citron DM; Tyrrell KL; Merriam CV
Antimicrob Agents Chemother; 2013 Oct; 57(10):4872-6. PubMed ID: 23877700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
